Targeted Protein Degradation: PROTACs, Molecular Glues, and the Future of Drugging Undruggable Targets
Targeted protein degradation is reshaping how researchers approach previously “undruggable” targets and offering a fresh toolkit for drug discovery.Rather than blocking a protein’s active site, degradation strategies remove the problematic protein from the cell, producing catalytic effects and opening therapeutic options across oncology, neurodegeneration, inflammation, and infectious disease.
How targeted degradation works
Two main modalities dominate the field: heterobifunctional degraders (commonly called PROTACs) and molecular glue degraders. Heterobifunctional molecules have two ligands joined by a linker: one binds the target protein, the other recruits an E3 ubiquitin ligase. Bringing those proteins together triggers ubiquitination of the target and subsequent proteasomal degradation.
Molecular glues, by contrast, are small molecules that stabilize or induce a direct interaction between an E3 ligase and a target, often using compact scaffolds to reshape protein surfaces.
Why this approach matters
– Access to “undruggable” targets: Proteins lacking clear enzymatic pockets—scaffolds, transcription factors, and regulatory proteins—can be targeted for removal rather than inhibition.
– Catalytic mechanism: One degrader molecule can trigger destruction of multiple copies of a target protein, enabling lower dosing and different pharmacodynamics compared with occupancy-driven inhibitors.
– Potential to overcome resistance: Some resistance mechanisms that arise from active-site mutations are less relevant when the mechanism of action is degradation rather than blockade.
– Expanded therapeutic modalities: Degraders enable transient or tunable protein knockdown, useful for targets where permanent inhibition is undesirable.
Key challenges in discovery and development
– Pharmacokinetics and oral bioavailability: Designing large, heterobifunctional molecules with good cell permeability and metabolic stability remains difficult. Linker chemistry and polarity management are critical.
– Selectivity and off-target degradation: Unintended recruitment of proteins to E3 ligases can produce toxicity.
Proteome-wide degradation profiling is essential to characterize specificity.
– E3 ligase choice and tissue distribution: Most degraders exploit a small set of E3 ligases; expanding the ligase toolbox helps tailor degradation to tissue or cell type and can mitigate resistance.
– Resistance mechanisms: Loss or mutation of the recruited E3 ligase, adaptative cellular responses, or target mutations that prevent ternary complex formation can reduce efficacy.
Strategies researchers are using
– Structure-guided design and ternary complex modeling to optimize cooperativity and selectivity.
– Linker libraries and scaffold-hopping to balance potency with drug-like properties.
– Chemoproteomics and quantitative proteomics to map degradation profiles and identify off-targets early.
– Discovery of new E3 ligase binders, including tissue-selective ligases, to expand targeting options and improve safety.
– Alternative degradation pathways such as lysosome-targeting chimeras and autophagy-based approaches for extracellular or membrane proteins.
Clinical and translational outlook
Targeted degradation is moving from a promising concept to practical therapeutics, with molecules demonstrating activity across multiple disease areas and informing combination strategies with existing treatments.
The technology’s ability to target traditionally intractable biology continues to inspire novel target classes and therapeutic hypotheses, while advances in delivery, linker chemistry, and proteome-wide safety profiling are reducing translational risk.
For drug discovery teams focused on challenging targets, targeted protein degradation offers a compelling path: a mechanism that reimagines what is druggable and equips researchers with new levers to modulate disease biology with precision.